144 - MBX Biosciences, Inc. (0001776111) (Subject)

S-3ASR - MBX Biosciences, Inc. (0001776111) (Filer)

S-8 - MBX Biosciences, Inc. (0001776111) (Filer)

10-K - MBX Biosciences, Inc. (0001776111) (Filer)

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

SCHEDULE 13D/A - MBX Biosciences, Inc. (0001776111) (Subject)

SCHEDULE 13G/A - MBX Biosciences, Inc. (0001776111) (Subject)

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

3 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

3 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

Barclays initiated coverage of MBX Biosciences with a rating of Overweight and set a new price target of $66.00

Goldman initiated coverage of MBX Biosciences with a rating of Sell and set a new price target of $18.00

TD Cowen initiated coverage of MBX Biosciences with a rating of Buy

Truist initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $50.00

Jefferies resumed coverage of MBX Biosciences with a rating of Buy and set a new price target of $36.00

Mizuho initiated coverage of MBX Biosciences with a rating of Outperform and set a new price target of $38.00

Oppenheimer initiated coverage of MBX Biosciences with a rating of Outperform and set a new price target of $38.00

Citizens JMP initiated coverage of MBX Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

Guggenheim initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $44.00

Stifel initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $40.00

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stag

CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer (CBO). Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries. "Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships

In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows. CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP). "We are very encouraged by the outcome of our End-of-

CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP). "We are very encouraged by the outcome of our End-of-Phase 2 meeting and the constructive feedback supporting our planned Phase 3 trial for canvuparatide," said

CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will participate in the following upcoming March investor conferences: Citizens Life Sciences Conference Date: Tuesday, March 10, 2026Format: Fireside chat and 1x1 meetingsTime: 9:00 a.m. – 9:25 a.m. ETLocation: Miami, FL UBS Biotech Summit Miami – Catalyst for Change Date: Tuesday, March 10

CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at and participate in the following upcoming investor conferences: 36th Oppenheimer Annual Healthcare Life Sciences Conference (Virtual) Date: Wednesday, February 25, 2026Format: Fireside chat and 1x1 meetingsTime: 11:20 a.m. – 11:50 a.m. ET TD Cowen 46th Annual Health Care Confe

CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Laurie Stelzer as an independent director on the Company's Board of Directors and as chairperson of the board's audit committee. Ms. Stelzer brings decades of executive and financial leadership experience with extensive corporate governance, financial oversight, and accounting experience. "I am thrilled to welcome Laurie Stelzer to the Company's Board as an independent director,"

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing Strong cash position: preliminary unaudited cash, cash equivalents and marketable securities of approximately $373.7 million as of December 31, 2025, expected

CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco being held on January 12-15, 2026. 44th Annual J.P. Morgan Healthcare Conference Date: Tuesday, January 13, 2026Format: Company presentation and 1x1 meetingsTime: 3:45 p.m. PT/ 6:45 p.m. ETLocation: San Francisco, California The live webcast can be accessed

CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present and participate in the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4. 37th Annual Piper Sandler Healthcare Conference Date: Tuesday, December 2, 2025Format: Fireside chat and 1x1 meetingsTime: 4:00 p.m. – 4:25 p.m. ETLocation: New York, NY The live webcast can be accesse

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stag

CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer (CBO). Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries. "Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships

CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Laurie Stelzer as an independent director on the Company's Board of Directors and as chairperson of the board's audit committee. Ms. Stelzer brings decades of executive and financial leadership experience with extensive corporate governance, financial oversight, and accounting experience. "I am thrilled to welcome Laurie Stelzer to the Company's Board as an independent director,"

CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clinical Development. "Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "Andreas' deep expertise in endocrinology and proven track record of lea

Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate

CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief

Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind., March 05, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointments of Chatan Charan, Ph.D. as Senior Vice President, Pharmaceutical Development and Chemistry, Manufacturing and Controls (CMC) and Mark Hope as Senior Vice President, Regulatory and Quality. "We are excited to welcome Chatan and Mark, who wi

Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney biomarkers All patients completed the 12-week AvailTM trial and 94% entered the OLE Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial Preparation underway to initiate Phase 3 trial in 2026 Company to host conference call at 8:00 am ET today CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22. The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast he

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou

SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)